Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

S. Gadgeel; A.T. Shaw; F. Barlesi; L. Crino; J.C.H. Yang; A.M. Dingemans; D.W. Kim; F. de Marinis; M. Schulz; S.Y. Liu; R. Gupta; V. Smoljanovic; S.H.I. Ou

doi:10.2147/LCTT.S209231

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

S. Gadgeel, A.T. Shaw, F. Barlesi, L. Crino, J.C.H. Yang, A.M. Dingemans, D.W. Kim, F. de Marinis, M. Schulz, S.Y. Liu, R. Gupta, V. Smoljanovic, S.H.I. Ou^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	125-130
Number of pages	6
Journal	Lung Cancer: Targets and Therapy
Volume	10
DOIs	https://doi.org/10.2147/LCTT.S209231
Publication status	Published - 1 Jan 2019

Keywords

alectinib
non-small-cell lung cancer
np28673
np28761
time to response
NP28673
NP28761

Access to Document

10.2147/LCTT.S209231

Cite this

Gadgeel, S., Shaw, A. T., Barlesi, F., Crino, L., Yang, J. C. H., Dingemans, A. M., Kim, D. W., de Marinis, F., Schulz, M., Liu, S. Y., Gupta, R., Smoljanovic, V., & Ou, S. H. I. (2019). Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. Lung Cancer: Targets and Therapy, 10, 125-130. https://doi.org/10.2147/LCTT.S209231

Gadgeel, S. ; Shaw, A.T. ; Barlesi, F. ; Crino, L. ; Yang, J.C.H. ; Dingemans, A.M. ; Kim, D.W. ; de Marinis, F. ; Schulz, M. ; Liu, S.Y. ; Gupta, R. ; Smoljanovic, V. ; Ou, S.H.I. / Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. In: Lung Cancer: Targets and Therapy. 2019 ; Vol. 10. pp. 125-130.

@article{8c524570f9e34f5faa9b15f94752b683,

title = "Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies",

keywords = "alectinib, non-small-cell lung cancer, np28673, np28761, time to response, NP28673, NP28761",

author = "S. Gadgeel and A.T. Shaw and F. Barlesi and L. Crino and J.C.H. Yang and A.M. Dingemans and D.W. Kim and {de Marinis}, F. and M. Schulz and S.Y. Liu and R. Gupta and V. Smoljanovic and S.H.I. Ou",

year = "2019",

month = jan,

day = "1",

doi = "10.2147/LCTT.S209231",

language = "English",

volume = "10",

pages = "125--130",

journal = "Lung Cancer: Targets and Therapy",

issn = "1179-2728",

publisher = "Dove Medical Press Ltd",

}

Gadgeel, S, Shaw, AT, Barlesi, F, Crino, L, Yang, JCH, Dingemans, AM, Kim, DW, de Marinis, F, Schulz, M, Liu, SY, Gupta, R, Smoljanovic, V & Ou, SHI 2019, 'Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies', Lung Cancer: Targets and Therapy, vol. 10, pp. 125-130. https://doi.org/10.2147/LCTT.S209231

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. / Gadgeel, S.; Shaw, A.T.; Barlesi, F.; Crino, L.; Yang, J.C.H.; Dingemans, A.M.; Kim, D.W.; de Marinis, F.; Schulz, M.; Liu, S.Y.; Gupta, R.; Smoljanovic, V.; Ou, S.H.I.

In: Lung Cancer: Targets and Therapy, Vol. 10, 01.01.2019, p. 125-130.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

AU - Gadgeel, S.

AU - Shaw, A.T.

AU - Barlesi, F.

AU - Crino, L.

AU - Yang, J.C.H.

AU - Dingemans, A.M.

AU - Kim, D.W.

AU - de Marinis, F.

AU - Schulz, M.

AU - Liu, S.Y.

AU - Gupta, R.

AU - Smoljanovic, V.

AU - Ou, S.H.I.

PY - 2019/1/1

Y1 - 2019/1/1

KW - alectinib

KW - non-small-cell lung cancer

KW - np28673

KW - np28761

KW - time to response

KW - NP28673

KW - NP28761

U2 - 10.2147/LCTT.S209231

DO - 10.2147/LCTT.S209231

M3 - Article

VL - 10

SP - 125

EP - 130

JO - Lung Cancer: Targets and Therapy

JF - Lung Cancer: Targets and Therapy

SN - 1179-2728

ER -